Immunovant Inc (IMVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
Immunovant Inc (IMVT) Financials: Revenue, Profit and Cash Flow
Immunovant reported revenue of $0 for the fiscal year ended Mar 31, 2026. That year, net income was -$505.61M, operating cash flow was -$407.31M and free cash flow was -$407.32M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$97.25M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Mar 2026, with an operating loss of $532.90M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $0 | N/A | N/A | N/A | N/A |
| Mar 2025 | $0 | N/A | N/A | N/A | N/A |
| Mar 2024 | $0 | N/A | N/A | N/A | N/A |
| Mar 2023 | $0 | N/A | N/A | N/A | N/A |
| Mar 2022 | $0 | N/A | N/A | N/A | N/A |
| Mar 2021 | $0 | N/A | N/A | N/A | N/A |
| Mar 2020 | $0 | N/A | N/A | N/A | N/A |
| Mar 2019 | N/A | N/A | N/A | N/A | N/A |
| Dec 2018 | N/A | N/A | N/A | N/A | N/A |
| Mar 2018 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Dec 2018 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $409.00K | $377.00K | $231.00K | $1.32M | $1.23M | $998.00K | $21.00K | N/A | N/A | N/A |
| Gross profit | -$409.00K | -$377.00K | -$231.00K | -$1.32M | -$1.23M | -$998.00K | -$21.00K | N/A | N/A | N/A |
| Research and development | $456.66M | $360.92M | $212.93M | $160.26M | $101.81M | $68.60M | $47.93M | $25.73M | $0 | $135.26M |
| Operating income | -$532.90M | -$438.15M | -$270.21M | -$208.28M | -$156.03M | -$108.12M | -$59.68M | -$450 | -$450 | -$136.74M |
| Net income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M | -$107.43M | -$66.39M | -$450 | -$450 | -$136.74M |
| EBITDA | -$504.98M | -$412.57M | -$258.54M | -$198.28M | N/A | -$108.05M | N/A | N/A | N/A | N/A |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $7.09M | $0 | $0 | $0 | $0 | $160.00K | $0 | $0 | $0 | $1.50M | $0 |
| Gross profit | N/A | $7.09M | N/A | -$101.00K | -$105.00K | -$107.00K | $80.00K | -$99.00K | -$89.00K | -$80.00K | $1.44M | -$58.00K |
| Operating income | -$104.16M | -$153.23M | -$159.55M | -$114.36M | -$131.76M | -$127.22M | -$113.83M | -$114.30M | -$115.74M | -$94.28M | -$80.88M | -$61.55M |
| Net income | -$97.25M | -$153.22M | -$147.86M | -$110.64M | -$126.50M | -$120.61M | -$106.45M | -$111.12M | -$109.12M | -$87.15M | -$75.32M | -$51.42M |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded short-term debt of $72.00K by $902.04M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $957.01M | $776.22M | $666.71M | $405.84M | $515.56M | $412.49M | $109.39M | $405.00K | $113.17K |
| Current assets | $948.82M | $767.66M | $665.77M | $404.33M | $512.93M | $409.01M | $109.08M | $325.00K | $113.17K |
| Cash and equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M | $100.57M | $325.00K | N/A |
| Total liabilities | $104.42M | $68.78M | $48.95M | $43.34M | $45.74M | $21.01M | $15.32M | $380.45K | $1.61M |
| Short-term debt | $72.00K | $98.00K | $138.00K | $1.17M | $1.15M | $1.18M | $3.19M | $300.00K | N/A |
| Shareholder equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M | $391.48M | $94.07M | $24.55K | -$1.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $760.97M | $852.49M | $957.01M | $1.05B | $582.96M | $661.44M | $776.22M | $420.93M | $515.71M | $589.68M | $666.71M | $711.45M |
| Total liabilities | $104.02M | $117.10M | $104.42M | $66.26M | $63.25M | $52.90M | $68.78M | $68.31M | $66.65M | $45.02M | $48.95M | $32.10M |
| Cash and equivalents | $722.27M | $797.80M | $902.11M | $994.52M | $521.87M | $598.91M | $713.97M | $374.69M | $472.94M | $560.00M | $635.37M | $690.94M |
| Shareholder equity | $656.95M | $735.39M | $852.59M | $986.13M | $519.71M | $608.54M | $707.45M | $352.62M | $449.05M | $544.66M | $617.76M | $679.34M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Dec 2018 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M | -$83.33M | -$53.36M | -$28.55M | N/A | -$128.30M |
| Capital expenditures | $8.00K | $759.00K | $360.00K | $197.00K | $254.00K | $210.00K | $31.00K | $52.00K | $0 | $52.00K |
| Free cash flow | -$407.32M | -$376.63M | -$214.59M | -$188.39M | -$106.37M | -$83.54M | -$53.39M | -$28.60M | N/A | -$128.35M |
| Investing cash flow | -$8.00K | -$759.00K | -$360.00K | -$197.00K | -$254.00K | -$210.00K | -$31.00K | -$52.00K | N/A | -$52.00K |
| Financing cash flow | $595.76M | $454.49M | $472.43M | $70.89M | $200.13M | $383.11M | $146.97M | $35.58M | $325.00K | $128.30M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$83.22M | -$124.41M | -$95.06M | -$92.33M | -$102.52M | -$117.41M | -$110.64M | -$100.39M | -$88.65M | -$76.20M | -$59.70M | -$47.10M |
| Capital expenditures | $0 | $0 | $8.00K | $0 | $0 | $0 | $201.00K | $180.00K | $196.00K | $182.00K | $150.00K | $131.00K |
| Free cash flow | -$83.22M | -$124.41M | -$95.07M | -$92.33M | -$102.52M | -$117.41M | -$110.84M | -$100.57M | -$88.84M | -$76.38M | -$59.85M | -$47.23M |
Frequently Asked Questions About IMVT
What is Immunovant's annual revenue?
Immunovant reported revenue of $0 for the fiscal year ended Mar 31, 2026.
Is Immunovant profitable?
No. Immunovant reported net income of -$505.61M for the fiscal year ended Mar 31, 2026.
How much free cash flow does IMVT generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$407.31M minus capital expenditures of $8.00K produced free cash flow of -$407.32M.
How much debt does Immunovant have?
The balance sheet dated Mar 31, 2026 reported short-term debt of $72.00K and cash and equivalents of $902.11M.
IMVT pages: Overview, Earnings, Forecast, Financials, Competitors